The pharmaceutical landscape is shifting beneath our feet. As the industry prepares for DCAT Week in New York City, the Dees Pharma team sat down to preview the critical trends dominating the 2026 global biopharmaceutical ecosystem. From high-stakes M&A to the ripple effects of the Biosecure Act, here is our take on where the market is headed.
The New M&A Paradigm: “High Performers” vs. “Ripe for Acquisition”
The traditional “Small Cap vs. Large Cap” debate is evolving. Isaac Jiganothin, our Supply Chain lead, suggests a more nuanced lens: High Performers vs. Low Performers. We aren’t seeing aggressive “winner-takes-all” takeovers; instead, we are entering an era of “win-win” partnerships. High-performing players are stepping in to stabilize assets that are financially ripe for acquisition, evidenced by multi-billion dollar moves from giants like Novo Holdings and Eli Lilly.
Inventory & The Vertical Integration Advantage
The funding environment has tightened, particularly for breakthrough therapies and small-cap startups. This “calling” of small pharma has created a contraction in the small-cap CDMO market.
According to Me Madhu, our CMC lead, the biggest differentiator today is vertical integration. Small CDMOs often lack the ability to manufacture their own custom consumables, such as buffers and media. In a world of volatile lead times, large CDMOs with in-house capabilities are streamlining manufacturing, leaving those reliant on third-party vendors struggling to keep pace.
Onshoring and the Biosecure Act
Manufacturing is coming home, but not without friction. With the Biosecure Act restricting federal agencies from procuring equipment or services from “Biotechnology Companies of Concern” (BCCs), the industry is on high alert. While the official list of designated firms is still being finalized by the OMB, the pressure to pivot away from certain overseas providers is already reshaping supply chains.
Senior Consultant, Process Development & CMC
